Recorded on Wednesday, August 17, 2022
Speaker: Alison Betts, PhD, Vice President of Scientific Collaborations and Fellow of Modeling & Simulation
Duration: 40 minutes
Many biotherapeutics in oncology have immune agonist properties and a Minimal Anticipated Biological Effect Level (MABEL) approach is recommended for selection of safe clinical starting dose. Selection of clinical starting dose is highly dependent upon the methodology chosen to determine MABEL. It can result in selection of overly conservative doses and many rounds of dose escalation before reaching efficacious doses in the clinic. In this webinar Dr. Betts discusses how mechanistic modeling approaches enable the integration of all relevant data from disparate experiments to select better clinical starting (and efficacious doses) in oncology.